FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Good day, everybody. My name is Jason Gerberry. I cover smid-cap biotech and especially pharmaceutical for Bank of America. I'm pleased to be introducing our next company presenter, FibroGen and new CEO, Enrique Conterno. FibroGen is -- most would know the company for its development of roxadustat for anemia associated with dialysis or renal disease, but the company also has an emerging early to mid-stage pipeline with pamrevlumab for fibrotic disorders.
So Enrique, first off, thanks for joining us at the conference on a virtual basis.
No, thank you, Jason. It's a pleasure for me to be here and talk about the progress we're making at FibroGen.
Questions & Answers
Great. I mean, look, you're no longer new to the role, but I imagine that the opportunity with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
